ASHM, October 2018 HIV PrEP Update for GPs and Practice Nurses This training will provide GPs, Nurses, and Health Professionals working in primary care an update on strategies available for the prevention of HIV transmission, focusing on prevention particularly pre-exposure prophylaxis (PrEP). – Date Tuesday, 23 October 2018 – Venue Mercure Grosvenor, 125 North Terrace, Adelaide SA...
Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM), 10 May 2018 ASHM has joined the call by leading Human T-Lymphotrophic Virus 1 (HTLV-1) researchers, clinicians and patients to take action on HTLV-1 by signing an open letter to the WHO, published in an abbreviated form in The Lancet. The letter calls on the WHO to support the promotion of proven, effective...
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM), 21 March 2018 ASHM congratulates the Federal Health Minister, the Hon. Greg Hunt’s announcement of a landmark in HIV prevention to approve HIV-prevention drugs – tenofovir with emtricitabine, known as PrEP – on the Pharmaceutical Benefits Scheme from 1 April, thereby providing broader access for any doctor or general...
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, October 2017 Registrations for these conferences are closing soon: The Australasian HIV&AIDS Conference The Australasian HIV&AIDS Conference is the premier HIV Conference in Australia and the Asia and Pacific region. The annual conference is run by ASHM as a platform for the dissemination and presentation of new and...
SAMESH is pleased to invite you – community members, clinicians, sector workers, anyone who may be interested – to their community forum, FACTS NOT FEAR: A forum on undetectable viral load. Join our panel of experts and community members to discuss the latest science about undetectable viral load and its role in preventing onward transmission of HIV, and to hear personal perspectives...
Joint position statement, Australia, June 2017 This joint Position Statement aims to strongly refute and reject the findings of the Cochrane Review report titled Direct-acting antivirals for chronic hepatitis C, published by the Cochrane Hepato‐Biliary Group on 6 June 2017. The Position Statement was prepared by the expert panel who published a Consensus Statement for Australian recommendations...